Ionis Pharmaceuticals, Inc. (NAS: IONS) Stock Analysis & Fundamentals

IONSIonis Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · ionis.com

54.65USD-0.15%Mkt Cap: 9.03B $P/E: —1d ago

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemi…

Headline	Source	Time
This week
Biogen Slumps As Alzheimer's Study Leaves 'More Questions Than Answers' Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months.	Investor's Business Daily	Jul 14
Morgan Stanley Raises its Price Target on Alnylam (ALNY) Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 10 Best Growth Stocks With Highest Upside Potential. On July 10, 2026, Morgan Stanley raised the firm’s price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $400 from $370 and kept an Equal Weight rating on the shares. On July 9, Raymond James raised the firm’s price target […]	Insider Monkey	Jul 14
Ionis Begins Dosing in Phase I/II Dravet Syndrome Study IONS doses first patient in the phase I/II ASCEND study of ION337, marking a key step in developing a potential disease-modifying treatment for Dravet syndrome.	Zacks	Jul 14
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details Biogen stock receives a bullish upgrade based on expectations the market will cheer the company’s detailed data on its experimental Alzheimer’s drug.	Barrons.com	Jul 13
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.	MarketBeat	Jul 13
Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?	Barrons.com	Jul 13
Panic grips Ionis Pharmaceuticals investors amid bad news spree	TheStreet	Jul 12
Older
Is Alnylam Pharmaceuticals (ALNY) Cheap As Rival Trial Failure Shifts ATTR CM Expectations?	Simply Wall St.	Jul 11
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up	24/7 Wall St.	Jul 10
Cathie Wood Dumps AMD, Doubles Down on Meta Stock	GuruFocus.com	Jul 10
Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?	Trefis	Jul 10
The Long Climb Back For Ionis Stock	Trefis	Jul 10
AstraZeneca (LSE:AZN) Misses Key Wainua Trial Goal Beyond Oncology	Simply Wall St.	Jul 10
Stocks to Watch: PepsiCo, Salesforce, AstraZeneca	The Wall Street Journal	Jul 9
Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump	Investor's Business Daily	Jul 9
Sector Update: Healthcare Stocks Softer Late Afternoon	MT Newswires	Jul 9
BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’	Stocktwits	Jul 9
AstraZeneca Slides 9.9% After Heart Drug Trial Misses Late-Stage Goal	GuruFocus.com	Jul 9
AstraZeneca and Ionis Stocks Sink on Trial Miss—Maybe Too Much	Barrons.com	Jul 9
FTSE 100 held back by AstraZeneca trial setback	PA Media: Money	Jul 9
Top Midday Stories: Tensions Rise as US, Iran Trade Attacks; Micron to Invest $3 Billion in US Semiconductor Supply Chain	MT Newswires	Jul 9
AstraZeneca Gets a Rare Clinical Black Eye	Moby	Jul 9
Is Ionis Pharmaceuticals, Inc. (IONS) Stock a Buy After Tryngolza’s FDA Approval?	Insider Monkey	Jul 8
IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study	Zacks	Jul 7
TimesSquare Mid Cap Growth Strategy Picks Ionis Pharmaceuticals (IONS) on Clinical Momentum	Insider Monkey	Jul 2
Mizuho Highlights Amgen (AMGN) Pipeline Potential With MariTide and Olpasiran	Insider Monkey	Jul 1
Ionis Pharmaceuticals (IONS) Signs Recordati Deal For Zilganersen Outside The U.S.	Simply Wall St.	Jun 28
Ionis Pharmaceuticals (IONS) Is Up 9.5% After FDA Expands Tryngolza Label For Severe Hypertriglyceridemia	Simply Wall St.	Jun 28
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati	Zacks	Jun 26
Ionis grants Recordati rights to zilganersen for Alexander disease	Hospital Management	Jun 26
FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia	Zacks	Jun 25
IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval	Stocktwits	Jun 24
Ionis, with new FDA nod, hits a ‘commercial inflection point’	BioPharma Dive	Jun 24
How Kardigan spun deal leftovers into a $400M IPO	BioPharma Dive	Jun 23
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now	InvestorPlace	Jun 19
Is lonis Pharmaceuticals, Inc. (IONS) Among the Best Genomics Stocks to Buy According to Analysts?	Insider Monkey	Jun 16
Intellia Surges; Can Its Gene-Editing Drug Solve The Chronic Treatment Problem?	Investor's Business Daily	Jun 15
Assessing Ionis Pharmaceuticals (IONS) Valuation After New Olezarsen Data Plans And Bullish Pipeline Updates	Simply Wall St.	Jun 6
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter	Motley Fool	May 31
Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?	Zacks	May 29
GSK’s hepatitis B drug touts functional curative potential in double Phase III win	Clinical Trials Arena	May 29
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside	Investing.com	May 28
A New, Powerful Cholesterol-Lowering Drug Is on the Horizon	The Wall Street Journal	May 27
Tryngolza shows efficacy in severe hypertriglyceridemia as approval verdicts loom	Clinical Trials Arena	May 27
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts	MarketBeat	May 26
Citi Names 2 Biotech Stocks ‘Top Picks’ for 2026	TipRanks	May 24
Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t a Slam Dunk	24/7 Wall St.	May 19
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls	The Fly	May 19
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference	MarketBeat	May 18

Industry Peers